Instructions to Authors

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer; and (d) Announcements of awards and prizes.

The principal aim of AR is to provide for the prompt publication of original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”. Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice):

1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php)
2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:
   John G. Delinassios
   International Institute of Anticancer Research (IIAR)
   Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS.
   1st km Kapandritiou-Kalamou Road
   P.O. Box 22, GR-19014 Kapandriti, Attiki
   GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2011 - International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
Prognostic Value of Persistent Peripheral Blood and Bone Marrow Lymphoblasts on Day 15 of Therapy in Childhood Acute Lymphoblastic Leukemia as Detected by Flow Cytometry. A. JAWORSKA-POSADZY, J. STYCZYNISKI, M. KUBICKA, R. DEBSKI, B. RAFINSKA-KURYLO, B. KOLODZIEJ, M. POGORZALA, M. WYSOCKI (Bydgoszcz, Poland) .......................................................................................................................... 1453

Association between Genetic Polymorphisms Related to DNA Repair or Xenobiotic Pathways and Gastric Premalignant Conditions. T. TAHARA, T. SHIBATA, M. NAKAMURA, H. YAMASHITA, D. YOSHIOKA, M. OKUBO, J. YONEMURA, Y. KAMIYA, T. ISHIZUKA, Y. NAKAGAWA, M. NAGASAKA, M. IWATA, I. HIRATA, T. ARISAWA (Toyoake; Ishikawa, Japan) ......................................................................................... 1459


Continuous Saline Bladder Irrigation after Transurethral Resection Is a Prophylactic Treatment Choice for Non-muscle Invasive Bladder Tumor. T. ONISHI, T. SASAKI, A. HOSHINA, T. YABANA (Ise; Mie, Japan) ............................................................................... 1471

Time to Castration Resistance Is an Independent Predictor of Castration-resistant Prostate Cancer Survival. E. BOURNAKIS, E. EFSTATHIOU, A. VARKARIS, S. WEN, M. CHRISOFOΣ, C. DELIVELΙOTIS, C. ALAMANIS, I. ANASTASIΟU, C. CONSTANTINIDES, A. BAMIAS, M.A. DIMOPOULOS (Athens, Greece; Houston, TX, USA) ............................................................................................................ 1475

Phase II Trial of Preoperative Chemotherapy for Breast Cancer: Japan Breast Cancer Research Network (JBCRN)-02 Trial. S. IWASE, D. YAMAMOTO, Y. KURODA1, T. KAWAGUCHI, K. KITAMURA, H. ODAGIRI, S. TERAMOTO, K. AKAZAWA, Y. NAGUMO (Tokyo; Hirakata, Osaka; Fukuoka; Hirosaki; Niigata, Japan) .............................................................................................. 1483

ABSTRACTS OF THE 4TH INTERNATIONAL SYMPOSIUM ON VITAMIN D AND ANALOGS IN CANCER PREVENTION AND THERAPY, Homburg/Saar, Germany, 20-21 May, 2011 ........................................ 1489

Erratum ........................................................................................................................ ................ 1513

* Review (page 1105, 1161, 1249, 1387)
Single Nucleotide Polymorphisms of Integrin Alpha-2 and Beta-3 Genes Are not Associated with Relapse-free and Overall Survival in Colorectal Cancer Patients. G. HOFMANN, U. LANGSENLEHNER, T. LANGSENLEHNER, M. GLEHR, A. GERGER, G. ABSINGER, J. SZKANDERA, F. FUERST, H. SAMONIGG, P. KRIPL, W. RENNER (Graz; Fuerstenfeld, Austria) ................................................ 1373


* Review: The Involvement of Retroperitoneal Lymph Nodes in Primary Serous-papillary Peritoneal Carcinoma. A Systematic Review of the Literature. P.R. STEINHAGEN, J. SEHOULI (Berlin, Germany) .............................. 1387

The Expression of Sialic Fibronectin Correlates with Lymph Node Metastasis of Thyroid Malignant Neoplasms. H. TAKEYAMA, S. KYODA, T. OKAMOTO, Y. MANOME, M. WATANABE, S. KINOSHITA, K. UCHIDA, A. SAKAMOTO, T. MORIKAWA (Tokyo, Japan) ........................................ 1395

PCA3 Urinary Test Versus 1H-MRSI and DCEMR in the Detection of Prostate Cancer Foci in Patients with Biochemical Alterations. V. PANEBIANCO, A. SCIARRA, E. DE BERARDINIS, G.M. BUSETTO, D. LISH, V. BUONOCORE, V. GENTILE, F. DI SILVERIO, R. PASSARIELLO (Rome, Italy) ..................... 1399

Nonadherence to Imatinib Treatment in Patients with Gastrointestinal Stromal Tumors: The ADAGIO Study. F. MAZZEO, L. DUCK, E. JOOSENS, L. DIRIX, C. FOCAN, F. FORGET, S. DE GEEST, K. MUERMANS, M.-A. VAN LIERDE, K. MACDONALD, I. ABRAHAM, J. DE GRÈVE (Brussels; Ottignies; Antwerp; Liège; Libramont; Vilvoorde, Belgium; Basel; Switzerland; Earlysville, VA; Tucson, AZ, USA) ................................ 1407

Elevated Serum 8-OHdG Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. M. PYLVÄS, U. PUISTOLA, L. LAATIO, S. KAUPPILA, P. KARIHTALA (Oulu, Finland) ........................................... 1411

Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer. D.R. FOGELMAN, R.A. WOLFF, S. KOPETZ, M. JAVLE, C. BRADLEY, I. MOK, F. CABANILLAS, J.L. ABBRUZZEZE (Houston, TX; Francisco, CA, USA; San Juan, Puerto Rico) ........................................ 1417

The Value and Limitations of Contrast-enhanced Ultrasound in Detection of Prostate Cancer. A. STRAZDINA, G. KRUMINA, M. SPERGA (Riga, Latvia) ........................................................................ 1421

Impact of Renal Failure on the Tumor Markers of Mesothelioma, N-ERC/Mesothelin and Osteopontin. K. SHIOMI, S. SHIOMI, Y. ISHINAGA, M. SAKURABA, Y. HAGIWARA, K. MIYASHITA, M. MAEDA, K. SUZUKI, K. TAKAHASHI, O. HINO (Tokyo; Gunma, Japan) ......................................................................................... 1427


High-risk Group for Locoregional Recurrence in Patients with Stage IB-IIB Squamous Cell Carcinoma of the Cervix Treated with Concurrent Chemoradiotherapy. M. HIRAKAWA, Y. NAGAI, T. TOITA, W. KUDAKA, M. INAMINE, K. OGAWA, S. MURAYAMA, Y. AOKI (Okayama, Japan) .......................................................... 1437

Sentinel Lymph Node Biopsy for Squamous Cell Carcinoma of the Extremities: Case Report and Review of the Literature. Y.Y. LIU, W.M. ROZEN, R. RAHDON (Geelong, VIC, Australia) ......................................................... 1443

Evaluation of Tumour Markers as Differential Diagnostic Tool in Patients with Suspicion of Liver Metastases from Breast Cancer. V. LISKA, L. HOLEBEC JR., V. TRESKA, J. VRZALOVA, T. SKALICKY, A. SUTNAR, S. KORMUNA, J. BRUHA, O. VYCITAL, J. FINEK, M. PESTA, L. PECEN, O. TOPOLCAN (Prague, Czech Republic) .................................................................................. 1447

Contents continued on the preceding page
Human EAG1 Potassium Channels in the Epithelial-to-Mesenchymal Transition in Lung Cancer Cells. I. RESTREPO-ANGULO, C. SÁNCHEZ-TORRES, J. CAMACHO (Mexico City, Mexico) ................................................................. 1265

Claudin-4: A Potential Therapeutic Target in Chemotherapy-resistant Ovarian Cancer. H. YOSHIDA, T. SUMI, X. ZHI, T. YASUI, K.-I. HONDA, O. ISHIKO (Osaka, Japan) ................................................................. 1271


Aberrant Methylation of the Vimentin Gene in Hepatocellular Carcinoma. Y. KITAMURA, A. SHIRAHATA, K. SAKURABA, T. GOTO, H. MIZUKAMI, M. SAITO, K. ISHIBASHI, G. KIgAWA, H. NEMOTO, Y. SANADA, K. HIBI (Yokohama, Japan) .......................................................................................................................... 1289


Involvement of Cancer Biomarker C7orf24 in the Growth of Human Osteosarcoma. D. UEJIMA, K. NISHIJO, Y. KAJITA, T. ISHIBE, T. AOYAMA, S. KAGEYAMA, H. IWAKI, T. NAKAMURA, H. IIDA, T. YOSHIKI, J. TOGUCHIDA (Kyoto; Osaka; Shiga, Japan) ................................................................. 1297

Induction of MMP-13 Expression in Bone-metastasizing Cancer Cells by Type I Collagen through Integrin α1β1 and α2β1-p38 MAPK Signaling. S. IBARAGI, T. SHIMO, N.M. HASSAN, S. ISOWA, N. KURIO, H. MANDAI, S. KODAMA, A. SASAKI (Okayama, Japan) ................................................................................................................................. 1307

Prognostic Impact of CD133 Immunoexpression in Node-negative Invasive Breast Carcinomas. A. IENI, G. GIUFFRÉ, V. ADAMO, G. TUCCARI (Messina, Italy) ........................................................................................................................................................................ 1315

Chitosan Derivatives Inhibit Cell Proliferation and Induce Apoptosis in Breast Cancer Cells. M. JIANG, H. OUYANG, P. RUAN, H. ZHAO, Z. PI, S. HUANG, P. XI, M. CREPIN (Wuhan; Guangzhou; Shiyan, PR China; Bobigny, France) ........................................................................................................................................ 1321

Tumour-derived Microvesicles Contain Interleukin-8 and Modulate Production of Chemokines by Human Monocytes. M. BAJ-KRZYWORZEKA, K. WĘGLARCZYK, B. MYTAR, R. SZATANEK, J. BARAN, M. ZEMBALA (Cracow, Poland) ........................................................................................................................................... 1329

Abnormal Methylation of Histone Deacetylase Genes: Implications on Etiology and Epigenetic Therapy of Astrocytomas. M.V. GOMES, K.S. BORGES, D.A. MORENO, R.G. QUEIROZ, H.R. MACHADO, C.G. CARLOTTI JR., C.A. SCIREDI, L.G. TONE (Londrina, PR; Ribeirão Preto, SP, Brazil) ................................................................. 1337

Differential Apoptotic Effects of Novel Quinuclidinone Analogs 8a and 8b in Normal and Lung Cancer Cell Lines. A. MALKI, S. BERGMEIER (Athens, OH, USA; Alexandria, Egypt) ........................................................................................................................................... 1345

Polymorphisms of the CYP1A1, CYP2E1 and XRCC1 Genes and Cancer Risk in a Southern Italian Population: A Case–Control Study. G. BIANCHINO, A. CITTAADINI, V. GRIECO, A. TRAFICANTE, A. ZUPA, G. IMPROTA, M. AIETA, A. SGAMBATO (Potenza; Rome, Italy) ........................................................................................................................................................................ 1359

Clinical Studies

Effect of Tamoxifen or Anastrozole on Steroid Sulfatase Activity and Serum Androgen Concentrations in Postmenopausal Women with Breast Cancer. S.J. STANWAY, C. PALMIERI, F.Z. STANCZYK, E.J. FOLKERD, M. DOWSETT, R. WARD, R.C. COOMBES, M.J. REED, A. PUROHIT (London, UK; Los Angeles, CA, USA) ........................................................................................................................................... 1367

Contents continued on the preceding page
Ras/Raf/MEK/ERK Pathway Is Associated with Lung Metastasis of Osteosarcoma in an Orthotopic Mouse Model. Y. YU, F. LUK, J.-L. YANG, W.R. WALSH (Sydney, NSW, Australia) ................................................................. 1147

The Effect of PTEN on Serotonin Synthesis and Secretion from the Carcinoid Cell Line BON. S.R. SILVA, Y.Y. ZAYTSEVA, L.N. JACKSON, E.Y. LEE, H.L. WEISS, K.A. BOWEN, C.M. TOWNSEND JR., B.M. EVERS (Lexington, KY; Galveston, TX, USA) .................................................................................. 1153

* Review: Body Fluid Biomarkers for Early Detection of Head and Neck Squamous Cell Carcinomas. K.-D. LEE, H.-S. LEE, C.-H. JEON (Busan; Daegu, South Korea) ........................................................................................................ 1161

Beta-(1-3),(1-6)-D-glucan Enhances the Effect of Low-dose Cyclophosphamide Treatment on A20 Lymphoma in Mice. U. HARNACK, K. ECKERT, G. PECHER (Berlin, Germany) .................................................................................. 1169

Pigment Epithelial-derived Factor Inhibits c-FLIP Expression and Assists Ciglitazone-induced Apoptosis in Hepatocellular Carcinoma. L.-J. LAI, T.-C. HO (Chia-Yi; Tao-Yuan; Taipei, Taiwan, ROC) .............................................................. 1173

MT477 Acts in Tumor Cells as an AURKA Inhibitor and Strongly Induces NRF-2 Signaling. P. JASINSKI, P. ZWOLAK, K. TERAI, R.I. VOGEL, D. BORJA-CACHO, A.Z. DUDEK (Minneapolis, MN, USA; Vienna, Austria) .................................................................................. 1181

Quantitative Comparison of Erythropoietin Receptor Levels in the Epithelial versus Endothelial Fractions of Primary Breast Tumors. C.P. MILLER, N. URBAN, C.A. BLAU (Seattle, WA, USA) .......................................................... 1189

Antitumor Effect of Novel HSP90 Inhibitor NVP-AUY922 against Oral Squamous Cell Carcinoma. T. OKUI, T. SHIMO, N.M. HASSAN, T. FUKAZAWA, N. KURIO, M. TAKAOKA, Y. NAOMOTO, A. SASAKI (Okayama, Japan) ........................................................................................................ 1197

EMMPRIN Expression in Oral SCC Is Regulated by FYN Kinase. D.M. RAMOS, D. DANG (San Francisco, CA, USA) ......................................................................................................................... 1205

Inverse Correlation between EGFR Mutation and FHIT, RASSF1A and RUNX3 Methylation in Lung Adenocarcinoma: Relation with Smoking Status. N. YANAGAWA, G. TAMURA, H. OIZUMI, M. ENDOH, M. SADAHIRO, T. MOTOYAMA (Yamagata, Japan) ................................................................. 1211

Increased Apoptosis of Host Cells and Tumor Cells in the Invasion Front of Colorectal Liver Metastases. O.R. BANDAPALLI, N. HARIRI, S. MACHER-GÖPPINGER, C. KAHLERT, P. SCHIRMACHER, K. BRAND (Heidelberg, Germany) ........................................................................................................ 1215

Sunitinib Suppresses Tumor Growth and Metastases in a Highly Metastatic Mouse Mammary Cancer Model. Y. TANAKA, M.-A. SHIBATA, J. MORIMOTO, Y. OTSUKI (Osaka, Japan) ........................................................................................................ 1225

Revitalization of Human Bone after Extracorporeal High Hydrostatic Pressure Treatment. J. SCHAUWECKER, R. VON EISENHART-ROTHE, R. BURGKART, J. TUEBEL, M. SCHMITT, W. MITTELMEIER, P. DIEHL (Munich; Rostock, Germany) .................................................................................. 1235

Enhancement of Dectin-2 Gene Expression by Lignin–Carbohydrate Complex from Lentinus edodes Mycelia Extract (LEM) in a Mouse Macrophage-like Cell Line. T. KUSHIDA, T. MAKINO, M. TOMOMURA, A. TOMOMURA, H. SAKAGAMI (Tokyo; Saitama, Japan) .. 1241

* Review: Potential Tumor-tropic Effect of Genetically Engineered Stem Cells Expressing Suicide Enzymes to Selectively Target Invasive Cancer in Animal Models. S.U. KIM, E.-B. JEUNG, Y.-B. KIM, M.-H. CHO, K.-C. CHOI (Vancouver, BC, Canada; Chungbuk; Seoul, South Korea) ........................................................................................................ 1249

Two-dimensional Gel Electrophoresis Using Immobilized pH Gradient Strips and Flamingo™ Fluorescent Gel Stain Identified Non-nuclear Proteins Possibly Related to Malignant Tumour Progression. Y. KURAMITSU, E. HAYASHI, F. OKADA, X. ZHANG, Y. UEYAMA, K. NAKAMURA (Ube; Yonago, Japan) ........................................................................................................ 1259

Contents continued on the preceding page